Live Chat

CFD's zijn complexe instrumenten en gaan gepaard met een hoog risico snel kapitaal te verliezen als gevolg van hefboommechanismen. 74% an de retailbeleggers lijdt verlies op de handel in CFD's met deze aanbieder. U dient zorgvuldig te overwegen of u begrijpt hoe CFD's werken en of u het zich kunt veroorloven om hoge risico's te nemen op het verliezen van uw kapitaal.

Close

Handelen Vir Biotechnology VIR

VirBiotechnology live grafieken

instrument_fundamentals

Weekly Search
Weekly
Daily
Datum Sluit Verandering % verandering Openen Piek Bodem

Nieuws

Info

Spread

0.05

Spread (%)

0.6562 %

Hefboom

1:5

Dagrente kopen

-0.0597 %

Dagrente verkopen

-0.0292 %

Valuta

USD

Openingstijden

Markt gesloten

Maandag

13:31 - 19:59

Dinsdag

13:31-19:59

Woensdag

13:31-19:59

Donderdag

13:31-19:59

Vrijdag

13:31-19:59

instr__analysis_statistics

Openen

---

Vorige Sluiten

---

52-weekse hoog/laag

--- – ---

Beurswaarde

1342732800

Uitstaande aandelen

137720000

Datum winstcijfer (volgende)

0000-00-00

Div. rend.

Ex-dividenddatum

Jaarlijks verwachte dividendpercentage

0

Jaarlijks verwachte dividendrendement

0

Winst per aandeel

-3.87

Meer informatie over dit instrument

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Gerelateerde instrumenten

Activa
Verkoop
Koop
% verandering
Gerelateerde instrumenten

Laatste marktnieuws

Blijf op de hoogte van het laatste financiële nieuws uit de hele wereld.

Donderdag, 7 November 2024

Week ahead: Trump trade, inflation data, Disney earnings

Donderdag, 7 November 2024

Stock markets today: Notable stocks closed at record highs Thursday

Donderdag, 7 November 2024

Bitcoin Price Reaches $75,358: Market Analysis and Trading Patterns

Donderdag, 7 November 2024

TUI share price rise on strong Q3 earnings beat

Donderdag, 7 November 2024

Forex market update: Japanese Yen and Australian Dollar news

Woensdag, 6 November 2024

U.S. presidential election market volatility drives Bitcoin prices to reach a historic high

Stock market rally

Dinsdag, 5 November 2024

US Election Results Trigger Stock Gains Across Europe, Asia, and US

US Election Trump's victory

Dinsdag, 5 November 2024

Trump Victory Spurs Market Gains and Economic Shift Expectations

Trustpilot
Live Chat